cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2019.6.n683cardio-683Research ArticleХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬCHRONIC HEART FAILUREСистематический анализ ролей микроэлементов в профилактике и терапии хронической сердечной недостаточностиSystematic Analysis of the Roles of Trace Elements in the Prevention and Treatment of Chronic Heart FailureГромоваО. А.GromovaO. A.

Gromova Olga A. – professor.

Moscow

unesco.gromova@gmail.comТоршинИ. Ю.TorshinI. Yu.info@ossn.ruКобалаваЖ. Д.KobalavaZh. D.info@ossn.ruНазаренкоА. Г.NazarenkoA. G.info@ossn.ruФГУ ФИЦ «Информатика и управление»; Центр хранения и анализа больших данных, МГУ им. М. В. ЛомоносоваРоссияFederal Research Center for Informatics and Management; Center for Big Data Storage and Analysis, Moscow State UniversityRussian FederationМГУ им. М. В. ЛомоносоваРоссияMoscow State UniversityRussian FederationФГАОУ «Национальный медицинский исследовательский центр нейрохирургии им. акад. Н. Н. Бурденко» Минздрава РоссииРоссияN. N. Burdenko National Scientific and Practical Center for NeurosurgeryRussian Federation2019050620195962634Copyright © Kardiomag, 20192019KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/683

Проведен систематический анализ 3 728 публикаций по взаимосвязи между микроэлементным статусом и хронической сердечной недостаточностью (ХСН). Выделены три основных направления исследований: 1) магний, электролиты и ХСН; 2) транскрипционные и антиоксидантные эффекты цинка, селена, меди; 3) железодефицитная анемия и ХСН. В настоящей работе рассмотрен комплекс взаимосвязей между обеспеченностью магнием и ХСН: воздействие магния на тонус сосудов, митохондрии, поддержание ритма сердца и восприимчивость кардиомиоцитов к адренергическому стимулированию. Показана целесообразность применения оротата магния для терапии ХСН.

Systematic analysis of 3 728 publications on the relationship between microelement status and chronic heart failure (CHF) was carried out. Three main areas of research have been identified: 1) magnesium, electrolytes and CHF; 2) the transcriptional and antioxidant effects of zinc, selenium, copper; 3) iron-deficiency anemia and CHF. In this paper, we consider a complex of relationships between the magnesium insufficiency and CHF, the effect of magnesium on vascular tone, mitochondria, heart rhythm and the susceptibility of cardiomyocytes to adrenergic stimulation. Using magnesium orotate for the treatment of CHF is a feasible approach to compensate magnesium insufficiency in patients with CHF.

хроническая сердечная недостаточностьгипомагниемияинтеллектуальный анализ данныхмагнеротchronic heart failurehypomagnesaemiadata miningmagnesium orotateРабота выполнена при поддержке грантов РФФИ 18‑07‑01022 и 18-07-00944ReferencesLima LF de, Barbosa F, Simões MV, Navarro AM. Heart failure, micronutrient profile, and its connection with thyroid dysfunction and nutritional status. Clinical Nutrition. 2019;38(2):800–5. DOI: 10.1016/j.clnu.2018.02.030Lima LF de, Barbosa F, Simões MV, Navarro AM. Heart failure, micronutrient profile, and its connection with thyroid dysfunction and nutritional status. Clinical Nutrition. 2019;38(2):800–5. DOI: 10.1016/j.clnu.2018.02.030Beedkar A, Parikh R, Deshmukh P. Heart Failure and the Iron Deficiency. The Journal of the Association of Physicians of India. 2017;65(11):79–80. PMID: 29322715Beedkar A, Parikh R, Deshmukh P. Heart Failure and the Iron Deficiency. The Journal of the Association of Physicians of India. 2017;65(11):79–80. PMID: 29322715Adamsson Eryd S, Borné Y, Melander O, Persson M, Smith JG, Hedblad B et al. Red blood cell distribution width is associated with incidence of atrial fibrillation. Journal of Internal Medicine. 2014;275(1):84–92. DOI: 10.1111/joim.12143Adamsson Eryd S, Borné Y, Melander O, Persson M, Smith JG, Hedblad B et al. Red blood cell distribution width is associated with incidence of atrial fibrillation. Journal of Internal Medicine. 2014;275(1):84–92. DOI: 10.1111/joim.12143Seelig MS. Interrelationship of magnesium and congestive heart failure. Wiener Medizinische Wochenschrift (1946). 2000;150(15– 16):335–41. PMID: 11105329Seelig MS. Interrelationship of magnesium and congestive heart failure. Wiener Medizinische Wochenschrift (1946). 2000;150(15– 16):335–41. PMID: 11105329Громова О.А., Калачева А.Г., Торшин И.Ю., Гришина Т.Р., Юдина Н.В. Калийсберегающие свойства магния. Кардиология. 2013;53(10):38-48Gromova O.A., Kalacheva A.G., Torshin I.Yu., Grishina T.R., Yudina N.V. Potassium-Preserving Properties of Magnesium. Kardiologiia. 2013;53(10):38–48. [Russian]Alehagen U, Aaseth J. Selenium and coenzyme Q10 interrelationship in cardiovascular diseases – A clinician’s point of view. Journal of Trace Elements in Medicine and Biology. 2015;31:157–62. DOI: 10.1016/j.jtemb.2014.11.006Alehagen U, Aaseth J. Selenium and coenzyme Q10 interrelationship in cardiovascular diseases – A clinician’s point of view. Journal of Trace Elements in Medicine and Biology. 2015;31:157–62. DOI: 10.1016/j.jtemb.2014.11.006Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Review of Clinical Pharmacology. 2015;8(2):189–99. DOI: 10.1586/17512433.2015.1011125Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Review of Clinical Pharmacology. 2015;8(2):189–99. DOI: 10.1586/17512433.2015.1011125Торшин И.Ю., Громова О.А. Экспертный анализ данных в молекулярной фармакологии. – М.: МЦНМО, 2012.-748с. ISBN 978-5-4439-0051-3Torshin I.Yu., Gromova O.A. Expert data analysis in molecular pharmacology. -M.: MCNMO; 2012. 748p. [Russian]. ISBN 978-5-4439-0051-3Торшин И.Ю., Гусев Е.И., Громова О.А., Калачева А.Г., Рудаков К.В. Мировой опыт изучения эффектов омега-3 полиненасыщенных жирных кислот: влияние на когнитивный потенциал и некоторые психические расстройства. Журнал неврологии и психиатрии им. C.C. Корсакова. 2011;111(11):79-86Torshin I.Yu., Gusev E.I., Gromova O.A., Kalacheva A.G., Rudakov K.V. International experience in studying effects of omega-3 polyunsaturated fatty acids: the influence on cognitive abilities and some mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(11):79–86. [Russian]Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. American Heart Journal. 1994;128(3):564–74. PMID: 8074021Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. American Heart Journal. 1994;128(3):564–74. PMID: 8074021Громова О.А., Гришина Т.Р., Торшин И.Ю., Лиманова О.А., Юдина Н.Ю., Калачева А.Г. Прием диуретиков провоцирует дефицит магния: тактика коррекции. Терапия. 2017;2(12):122-33Gromova O.A., Grishina T.R., Torshin I.Yu., Limanova O.A., Yudina N. Yu., Kalacheva A.G. Diuretics induce magnesium deficiency: tactics of correction. Th rapy. 2017;2(12):122–33. [Russian]Громова О.А., Лиманова О.А., Торшин И.Ю. Систематический анализ фундаментальных и клинических исследований как обоснование необходимости совместного использования эстрогенсодержащих препаратов с препаратами магния и пиридоксина. Акушерство, гинекология и репродукция. 2013;7(3):35-50Gromova O.A., Limanova O.A., Torshin I.Yu. Systematic analysis of fundamental and clinical research, as justification for the use of estrogen-containing drugs with the preparations of magnesium and pyridoxine. Obstetrics, gynecology and reproduction. 2013;7(3):35–50. [Russian]Громова О.А., Торшин И.Ю., Моисеев В.С., Сорокина М.А. О фармакологических взаимодействиях магния с антибиотиками и дефиците магния, возникающем в результате антибиотикотерапии. Терапия. 2017;1(11):135-43Gromova O.A., Torshin I.Yu., Moiseev V.S., Sorokina M.A. On the pharmacological interactions of antibiotics magnesium and on the magnesium deficiency ar as a result of antibiotic treatment. Therapy. 2017;1(11):135–43. [Russian]Newman KP, Neal MT, Roberts M, Goodwin KD, Hatcher EA, Bhattacharya SK. The importance of lost minerals in heart failure. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2007;5(4):295–9. PMID: 17979692Newman KP, Neal MT, Roberts M, Goodwin KD, Hatcher EA, Bhattacharya SK. The importance of lost minerals in heart failure. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2007;5(4):295–9. PMID: 17979692Oladapo OO, Falase AO. Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. African Journal of Medicine and Medical Sciences. 2000;29(3–4):265–8. PMID: 11714003Oladapo OO, Falase AO. Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. African Journal of Medicine and Medical Sciences. 2000;29(3–4):265–8. PMID: 11714003Struthers A. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovascular Research. 2004;61(4):663–70. DOI: 10.1016/j.cardiores.2003.11.037Struthers A. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovascular Research. 2004;61(4):663–70. DOI: 10.1016/j.cardiores.2003.11.037Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH. Role of Magnesium in Cardiovascular Diseases: Cardiology in Review. 2014;22(4):182–92. DOI: 10.1097/CRD.0000000000000003Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH. Role of Magnesium in Cardiovascular Diseases: Cardiology in Review. 2014;22(4):182–92. DOI: 10.1097/CRD.0000000000000003Громова О.А., Торшин И.Ю. Магний и «болезни цивилизации». – М.: ГЭОТАР-Медиа, 2018. - 800с. ISBN 978-5-9704-4527-3Gromova O.A., Torshin I.Yu. Magnesium and “diseases of civilization”. -М.: GEOTAR-Media; 2018. –800p. [Russian]. ISBN 978-5-9704-4527-3Громова О.А., Федотова Л.Э., Гришина Т.Р., Торшин И.Ю., Калачева А.Г., Лиманова О.А. Роль магния в формировании метаболического синдрома, коррекции избыточного веса и ожирения у детей и подростков. Педиатрия. Журнал им. Г.Н. Сперанского. 2014;93(2):123-33Gromova O.A., Fedotova L.E., Grishina T.R., Torshin I.Yu., Kalacheva A.G., Limanova O.A. The role of magnesium in the formation of metabolic syndrome, correction of overweight and obesity in children and adolescents. Pediatria. Journal named after G.N. Speransky. 2014;93(2):123–33. [Russian]Громова О.А., Торшин И.Ю., Сардарян И.С., Громов А.Н., Рудаков К.В. Перспективы применения препаратов на основе оротата магния у пациентов с сердечно-сосудистыми заболеваниями. Эффективная фармакотерапия. 2013;33:52-63Gromova O.A., Torshin I.Yu., Sardaryan I.S., Gromov A.N., Rudakov K.V. Magnesium orotate preparations in cardiovascular disorders: future directions. Effective pharmacotherapy. 2013;33:52–63. [Russian]Громова О.А., Калачева А.Г., Торшин И.Ю., Гришина Т.Р., Семенов В.А. Диагностика дефицита магния. концентрации магния в биосубстратах в норме и при различной патологии. Кардиология. 2014;54(10):63-71Gromova O.A., Kalacheva A.G., Torshin I.Yu., Grishina T.R., Semenov V.A. Diagnostics of Magnesium Deficiency and Measurements of Magnesium Concentrations in Biosubstrates in Norm and in Various Pathologies. Kardiologiia. 2014;54(10):63–71. [Russian]Громова О.А., Калачева А.Г., Торшин И.Ю., Рудаков К.В., Грустливая У.Е., Юдина Н.В. и др. Недостаточность магния - достоверный фактор риска коморбидных состояний: результаты крупномасштабного скрининга магниевого статуса в регионах РОССИИ. Фарматека. 2013;6(259):115-29Gromova O.A., Kalacheva A.G., Torshin I.Yu., Rudakov K.V., Grustlivaya U.E., Yudina N.V. et al. Magnesium deficiency - a significant risk factor for comorbid conditions: results of large-scale screening of magnesium status in Russian regions. Pharmateca. 2013;6(259):115–29. [Russian]Громова О.А., Лиманова О.А., Гоголева И.В., Гришина Т.Р., Громов А.Н., Егорова Е.Ю. и др. Анализ взаимосвязи между обеспеченностью магнием и риском соматических заболеваний у россиянок 18-45 лет методами интеллектуального анализа данных. Эффективная фармакотерапия. 2014;23:10-23Gromova O.A., Limanova O.A., Gogoleva I.V., Grishina T.R., Gromov A.N., Egorova E.Yu. et al. Interrelation between magnesium status and risk of somatic diseases in women aged 18-45 years old in Russia: the method of database mining. Effective pharmacotherapy. 2014;23:10–23. [Russian]Громова О.А., Торшин И.Ю., Кобалава Ж.Д., Сорокина М.А., Виллевальде С.В., Галочкин С.А. и др. Дефицит магния и гиперкоагуляционные состояния: метрический анализ данных выборки пациентов 18–50 лет лечебно-профилактических учреждений России. Кардиология. 2018;58(4):22-35. DOI: 10.18087/cardio.2018.4.10106Gromova O.A., Torshin I.Yu., Kobalava Zh.D., Sorokina M.A., Villevalde S.V., Galochkin S.A. et al. Deficit of Magnesium and States of Hypercoagulation: Intellectual Analysis of Data Obtained From a Sample of Patients Aged 18–50 years From Medical and Preventive Facilities in Russia. Kardiologiia. 2018;58(4):22–35. [Russian]. DOI: 10.18087/cardio.2018.4.10106Громова О.А., Торшин И.Ю., Калачева А.Г., Громов А.Н. Клинико-эпидемиологические исследования ишемической болезни сердца: роль недостаточности магния. Фарматека. 2014;18(291):48-59Gromova O.A., Torshin I.Yu., Kalacheva A.G., Gromov A.N. Clinical and epidemiological studies of coronary heart disease: the role of magnesium deficiency. Pharmateca. 2014;18(291):48–59. [Russian]Wannamethee SG, Papacosta O, Lennon L, Whincup PH. Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study. European Journal of Epidemiology. 2018;33(9):873–82. DOI: 10.1007/s10654-018-0388-6Gromova O.A., Torshin I.Yu., Kalacheva A.G., Gromov A.N. Clinical and epidemiological studies of coronary heart disease: the role of magnesium deficiency. Pharmateca. 2014;18(291):48–59. [Russian]Kunutsor SK, Khan H, Laukkanen JA. Serum magnesium and risk ofnewonsetheartfailureinmen: the Kuopio Ischemic Heart Disease Study. European Journal of Epidemiology. 2016;31(10):1035–43. DOI: 10.1007/s10654-016-0164-4Wannamethee SG, Papacosta O, Lennon L, Whincup PH. Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study. European Journal of Epidemiology. 2018;33(9):873–82. DOI: 10.1007/s10654-018-0388-6Громова О.А., Торшин И.Ю., Юдина Н.В., Егорова Е.Ю., Громов А.Н., Гришина Т.Р. Дефицит магния и нарушения регуляции тонуса сосудов. Кардиология. 2014;54(7):66-72Wannamethee SG, Papacosta O, Lennon L, Whincup PH. Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study. European Journal of Epidemiology. 2018;33(9):873–82. DOI: 10.1007/s10654-018-0388-6Gao X, Wang M, He X, Tang L, Liang J, Peng L et al. Decreased intralymphocytic magnesium content is associated with diastolic heart dysfunction in patients with essential hypertension. International Journal of Cardiology. 2011;147(2):331–4. DOI: 10.1016/j.ijcard.2010.12.092Kunutsor SK, Khan H, Laukkanen JA. Serum magnesium and risk ofnewonsetheartfailureinmen: the Kuopio Ischemic Heart Disease Study. European Journal of Epidemiology. 2016;31(10):1035–43. DOI: 10.1007/s10654-016-0164-4Dickinson HO, Nicolson D, Campbell F, Cook JV, Beyer FR, Ford GA et al. Magnesium supplementation for the management of primary hypertension in adults. Cochrane Database of Systematic Reviews. 2006;Jul 19(3):CD004640. DOI: 10.1002/14651858.CD004640.pub2Kunutsor SK, Khan H, Laukkanen JA. Serum magnesium and risk ofnewonsetheartfailureinmen: the Kuopio Ischemic Heart Disease Study. European Journal of Epidemiology. 2016;31(10):1035–43. DOI: 10.1007/s10654-016-0164-4Jee SH, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. American Journal of Hypertension. 2002;15(8):691–6. PMID: 12160191Gromova O.A., Torshin I.Yu., Yudina N.V., Egorova E.Yu., Gromov A.N., Grishina T.R. Magnesium Deficiency and Dys regulation of Vascular Tone. Kardiologiia. 2014;54(7):66–72. [Russian]Громова О.А., Торшин И.Ю., Рудаков К.В., Громов А.Н., Калачева А.Г. Систематический анализ магний-зависимых митохондриальных белков. Кардиология. 2014;54(9):86-92Gromova O.A., Torshin I.Yu., Yudina N.V., Egorova E.Yu., Gromov A.N., Grishina T.R. Magnesium Deficiency and Dys regulation of Vascular Tone. Kardiologiia. 2014;54(7):66–72. [Russian]Ahmed LA. Protective effects of magnesium supplementation on metabolic energy derangements in lipopolysaccharide-induced cardiotoxicity in mice. European Journal of Pharmacology. 2012;694(1–3):75–81. DOI: 10.1016/j.ejphar.2012.07.036Gao X, Wang M, He X, Tang L, Liang J, Peng L et al. Decreased intralymphocytic magnesium content is associated with diastolic heart dysfunction in patients with essential hypertension. International Journal of Cardiology. 2011;147(2):331–4. DOI: 10.1016/j.ijcard.2010.12.092Di Lullo L, Rivera R, Barbera V, Bellasi A, Cozzolino M, Russo Det al. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies. International Journal of Cardiology. 2016;217:16–27. DOI: 10.1016/j.ijcard.2016.04.170Gao X, Wang M, He X, Tang L, Liang J, Peng L et al. Decreased intralymphocytic magnesium content is associated with diastolic heart dysfunction in patients with essential hypertension. International Journal of Cardiology. 2011;147(2):331–4. DOI: 10.1016/j.ijcard.2010.12.092Gil KE, Pawlak A, Gil RJ, Frontczak-Baniewicz M, Bil J. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Advances in Medical Sciences. 2016;61(2):331–43. DOI: 10.1016/j.advms.2016.07.001Dickinson HO, Nicolson D, Campbell F, Cook JV, Beyer FR, Ford GA et al. Magnesium supplementation for the management of primary hypertension in adults. Cochrane Database of Systematic Reviews. 2006;Jul 19(3):CD004640. DOI: 10.1002/14651858.CD004640.pub2Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, Carrara GC. Magnesium and cardiovascular drugs: interactions and therapeutic role. Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societa Italiana Di Medicina Interna. 1999;14(1):40–5. PMID: 10528423Dickinson HO, Nicolson D, Campbell F, Cook JV, Beyer FR, Ford GA et al. Magnesium supplementation for the management of primary hypertension in adults. Cochrane Database of Systematic Reviews. 2006;Jul 19(3):CD004640. DOI: 10.1002/14651858.CD004640.pub2Wang A. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation. Pharmacy Practice. 2012;10(2):65–71. PMID: 24155819Jee SH, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. American Journal of Hypertension. 2002;15(8):691–6. PMID: 12160191Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger J et al. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Europace. 2009;11(7):892–5. DOI: 10.1093/europace/eup084Jee SH, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. American Journal of Hypertension. 2002;15(8):691–6. PMID: 12160191Tsukamoto T, Morita K, Naya M, Inubushi M, Katoh C, Nishijima K et al. Decreased Myocardial -Adrenergic Receptor Density in Relation to Increased Sympathetic Tone in Patients with Nonischemic Cardiomyopathy. Journal of Nuclear Medicine. 2007;48(11):1777–82. DOI: 10.2967/jnumed.107.043794Gromova O.A., Torshin I.Yu., Rudakov K.V., Gromov A.N., Kalacheva A.G. Systematic Analysis of Magnesium Dependent Mitochondrial Proteins. Kardiologiia. 2014;54(9):86–92. [Russian]Jin Y-T, Hasebe N, Matsusaka T, Natori S, Ohta T, Tsuji S et al. Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and β-adrenergic desensitization. American Journal of Physiology-Heart and Circulatory Physiology. 2007;292(3):H1593–9. DOI: 10.1152/ajpheart.00985.2006Gromova O.A., Torshin I.Yu., Rudakov K.V., Gromov A.N., Kalacheva A.G. Systematic Analysis of Magnesium Dependent Mitochondrial Proteins. Kardiologiia. 2014;54(9):86–92. [Russian]Wu Y-S, Chen C-C, Chien C-L, Lai H-L, Jiang S-T, Chen Y-C et al. Th type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA TAT3-dependent pathway. Journal of Biomedical Science. 2017;24(1):68. DOI: 10.1186/s12929-017-0367-3Ahmed LA. Protective effects of magnesium supplementation on metabolic energy derangements in lipopolysaccharide-induced cardiotoxicity in mice. European Journal of Pharmacology. 2012;694(1–3):75–81. DOI: 10.1016/j.ejphar.2012.07.036Громова О.А., Торшин И.Ю., Юргель И.С. Ретроспектива фармакокинетических исследований магниевых препаратов. Трудный пациент. 2009;7(6-7):42-6Ahmed LA. Protective effects of magnesium supplementation on metabolic energy derangements in lipopolysaccharide-induced cardiotoxicity in mice. European Journal of Pharmacology. 2012;694(1–3):75–81. DOI: 10.1016/j.ejphar.2012.07.036Торшин И.Ю., Громова О.А. Молекулярные механизмы воздействия оротата магния на сердечно-сосудистую систему. Рациональная фармакотерапия в кардиологии. 2008;4(5):63-6Di Lullo L, Rivera R, Barbera V, Bellasi A, Cozzolino M, Russo Det al. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies. International Journal of Cardiology. 2016;217:16–27. DOI: 10.1016/j.ijcard.2016.04.170Торшин И.Ю., Громова О.А., Федотова Л.Э., Калачева А.Г., Громов А.Н., Рудаков К.В. Хемоинформационный анализ молекулы оротовой кислоты указывает на противовоспалительные, нейропротекторные и кардиопротекторные свойства лиганда магния. Фарматека. 2013;13(266):95-104Di Lullo L, Rivera R, Barbera V, Bellasi A, Cozzolino M, Russo Det al. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies. International Journal of Cardiology. 2016;217:16–27. DOI: 10.1016/j.ijcard.2016.04.170Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. Cardiovascular Drugs and Therapy. 1998;12(Suppl 2):189–95. PMID: 9794093Gil KE, Pawlak A, Gil RJ, Frontczak-Baniewicz M, Bil J. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Advances in Medical Sciences. 2016;61(2):331–43. DOI: 10.1016/j.advms.2016.07.001Торшин И.Ю., Громова О.А., Калачева А.Г., Ощепкова Е.В., Мартынов А.И. Мета-анализ клинических воздействий оротата магния на сердечно-сосудистую систему. Терапевтический архив. 2015;87(6):88-97. DOI: 10.17116/terarkh201587688-97Gil KE, Pawlak A, Gil RJ, Frontczak-Baniewicz M, Bil J. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Advances in Medical Sciences. 2016;61(2):331–43. DOI: 10.1016/j.advms.2016.07.001Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). International Journal of Cardiology. 2009;131(2):293–5. DOI: 10.1016/j.ijcard.2007.11.022Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, Carrara GC. Magnesium and cardiovascular drugs: interactions and therapeutic role. Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societa Italiana Di Medicina Interna. 1999;14(1):40–5. PMID: 10528423Громова О.А., Торшин И.Ю., Калачева А.Г., Гришина Т.Р., Егорова Е.Ю. О циркадианном ритме и хронофармакологии оротата магния. Эффективная фармакотерапия. 2015;34:32-41Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, Carrara GC. Magnesium and cardiovascular drugs: interactions and therapeutic role. Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societa Italiana Di Medicina Interna. 1999;14(1):40–5. PMID: 10528423Wang A. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation. Pharmacy Practice. 2012;10(2):65–71. PMID: 24155819Wang A. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation. Pharmacy Practice. 2012;10(2):65–71. PMID: 24155819Wang A. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation. Pharmacy Practice. 2012;10(2):65–71. PMID: 24155819Wang A. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation. Pharmacy Practice. 2012;10(2):65–71. PMID: 24155819Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger J et al. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Europace. 2009;11(7):892–5. DOI: 10.1093/europace/eup084Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger J et al. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Europace. 2009;11(7):892–5. DOI: 10.1093/europace/eup084Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger J et al. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Europace. 2009;11(7):892–5. DOI: 10.1093/europace/eup084Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger J et al. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Europace. 2009;11(7):892–5. DOI: 10.1093/europace/eup084Tsukamoto T, Morita K, Naya M, Inubushi M, Katoh C, Nishijima K et al. Decreased Myocardial -Adrenergic Receptor Density in Relation to Increased Sympathetic Tone in Patients with Nonischemic Cardiomyopathy. Journal of Nuclear Medicine. 2007;48(11):1777–82. DOI: 10.2967/jnumed.107.043794Tsukamoto T, Morita K, Naya M, Inubushi M, Katoh C, Nishijima K et al. Decreased Myocardial -Adrenergic Receptor Density in Relation to Increased Sympathetic Tone in Patients with Nonischemic Cardiomyopathy. Journal of Nuclear Medicine. 2007;48(11):1777–82. DOI: 10.2967/jnumed.107.043794Tsukamoto T, Morita K, Naya M, Inubushi M, Katoh C, Nishijima K et al. Decreased Myocardial -Adrenergic Receptor Density in Relation to Increased Sympathetic Tone in Patients with Nonischemic Cardiomyopathy. Journal of Nuclear Medicine. 2007;48(11):1777–82. DOI: 10.2967/jnumed.107.043794Tsukamoto T, Morita K, Naya M, Inubushi M, Katoh C, Nishijima K et al. Decreased Myocardial -Adrenergic Receptor Density in Relation to Increased Sympathetic Tone in Patients with Nonischemic Cardiomyopathy. Journal of Nuclear Medicine. 2007;48(11):1777–82. DOI: 10.2967/jnumed.107.043794Jin Y-T, Hasebe N, Matsusaka T, Natori S, Ohta T, Tsuji S et al. Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and β-adrenergic desensitization. American Journal of Physiology-Heart and Circulatory Physiology. 2007;292(3):H1593–9. DOI: 10.1152/ajpheart.00985.2006Jin Y-T, Hasebe N, Matsusaka T, Natori S, Ohta T, Tsuji S et al. Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and β-adrenergic desensitization. American Journal of Physiology-Heart and Circulatory Physiology. 2007;292(3):H1593–9. DOI: 10.1152/ajpheart.00985.2006Jin Y-T, Hasebe N, Matsusaka T, Natori S, Ohta T, Tsuji S et al. Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and β-adrenergic desensitization. American Journal of Physiology-Heart and Circulatory Physiology. 2007;292(3):H1593–9. DOI: 10.1152/ajpheart.00985.2006Jin Y-T, Hasebe N, Matsusaka T, Natori S, Ohta T, Tsuji S et al. Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and β-adrenergic desensitization. American Journal of Physiology-Heart and Circulatory Physiology. 2007;292(3):H1593–9. DOI: 10.1152/ajpheart.00985.2006Wu Y-S, Chen C-C, Chien C-L, Lai H-L, Jiang S-T, Chen Y-C et al. Th type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA TAT3-dependent pathway. Journal of Biomedical Science. 2017;24(1):68. DOI: 10.1186/s12929-017-0367-3Wu Y-S, Chen C-C, Chien C-L, Lai H-L, Jiang S-T, Chen Y-C et al. Th type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA TAT3-dependent pathway. Journal of Biomedical Science. 2017;24(1):68. DOI: 10.1186/s12929-017-0367-3Wu Y-S, Chen C-C, Chien C-L, Lai H-L, Jiang S-T, Chen Y-C et al. Th type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA TAT3-dependent pathway. Journal of Biomedical Science. 2017;24(1):68. DOI: 10.1186/s12929-017-0367-3Wu Y-S, Chen C-C, Chien C-L, Lai H-L, Jiang S-T, Chen Y-C et al. Th type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA TAT3-dependent pathway. Journal of Biomedical Science. 2017;24(1):68. DOI: 10.1186/s12929-017-0367-3Gromova O.A., Torshin I.Yu., Yurgel’ I.S. Retrospective of pharmacokinetic studies of magnesium preparations. Difficult patient. 2009;7(6–7):42–6. [Russian]Gromova O.A., Torshin I.Yu., Yurgel’ I.S. Retrospective of pharmacokinetic studies of magnesium preparations. Difficult patient. 2009;7(6–7):42–6. [Russian]Gromova O.A., Torshin I.Yu., Yurgel’ I.S. Retrospective of pharmacokinetic studies of magnesium preparations. Difficult patient. 2009;7(6–7):42–6. [Russian]Gromova O.A., Torshin I.Yu., Yurgel’ I.S. Retrospective of pharmacokinetic studies of magnesium preparations. Difficult patient. 2009;7(6–7):42–6. [Russian]Torshin I.Yu., Gromova O.A. Molecular mechanisms of action of magnesium orotate on cardiovascular system. Rational Pharmacotherapy in Cardiology. 2008;4(5):63–6. [Russian]Torshin I.Yu., Gromova O.A. Molecular mechanisms of action of magnesium orotate on cardiovascular system. Rational Pharmacotherapy in Cardiology. 2008;4(5):63–6. [Russian]Torshin I.Yu., Gromova O.A. Molecular mechanisms of action of magnesium orotate on cardiovascular system. Rational Pharmacotherapy in Cardiology. 2008;4(5):63–6. [Russian]Torshin I.Yu., Gromova O.A. Molecular mechanisms of action of magnesium orotate on cardiovascular system. Rational Pharmacotherapy in Cardiology. 2008;4(5):63–6. [Russian]Torshin I.Yu., Gromova O.A., Fedotova L.E., Kalacheva A.G., Gromov A.N., Rudakov K.V. Ghemoinformational analysis molecule of orotic acid indicates anti-inflammatory, neuroprotective and cardioprotective properties of the ligand of magnesium. Pharmateca. 2013;13(266):95–104. [Russian]Torshin I.Yu., Gromova O.A., Fedotova L.E., Kalacheva A.G., Gromov A.N., Rudakov K.V. Ghemoinformational analysis molecule of orotic acid indicates anti-inflammatory, neuroprotective and cardioprotective properties of the ligand of magnesium. Pharmateca. 2013;13(266):95–104. [Russian]Torshin I.Yu., Gromova O.A., Fedotova L.E., Kalacheva A.G., Gromov A.N., Rudakov K.V. Ghemoinformational analysis molecule of orotic acid indicates anti-inflammatory, neuroprotective and cardioprotective properties of the ligand of magnesium. Pharmateca. 2013;13(266):95–104. [Russian]Torshin I.Yu., Gromova O.A., Fedotova L.E., Kalacheva A.G., Gromov A.N., Rudakov K.V. Ghemoinformational analysis molecule of orotic acid indicates anti-inflammatory, neuroprotective and cardioprotective properties of the ligand of magnesium. Pharmateca. 2013;13(266):95–104. [Russian]Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. Cardiovascular Drugs and Therapy. 1998;12(Suppl 2):189–95. PMID: 9794093Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. Cardiovascular Drugs and Therapy. 1998;12(Suppl 2):189–95. PMID: 9794093Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. Cardiovascular Drugs and Therapy. 1998;12(Suppl 2):189–95. PMID: 9794093Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. Cardiovascular Drugs and Therapy. 1998;12(Suppl 2):189–95. PMID: 9794093Torshin I.Yu., Gromova O.A., Kalacheva A.G., Oshchepkova E.V., Martynov A.I. Meta-analysis of clinical trials of cardiovascular effects of magnesium orotate. Therapeutic Archive. 2015;87(6):88–97. [Russian]. DOI: 10.17116/terarkh201587688-97Torshin I.Yu., Gromova O.A., Kalacheva A.G., Oshchepkova E.V., Martynov A.I. Meta-analysis of clinical trials of cardiovascular effects of magnesium orotate. Therapeutic Archive. 2015;87(6):88–97. [Russian]. DOI: 10.17116/terarkh201587688-97Torshin I.Yu., Gromova O.A., Kalacheva A.G., Oshchepkova E.V., Martynov A.I. Meta-analysis of clinical trials of cardiovascular effects of magnesium orotate. Therapeutic Archive. 2015;87(6):88–97. [Russian]. DOI: 10.17116/terarkh201587688-97Torshin I.Yu., Gromova O.A., Kalacheva A.G., Oshchepkova E.V., Martynov A.I. Meta-analysis of clinical trials of cardiovascular effects of magnesium orotate. Therapeutic Archive. 2015;87(6):88–97. [Russian]. DOI: 10.17116/terarkh201587688-97Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). International Journal of Cardiology. 2009;131(2):293–5. DOI: 10.1016/j.ijcard.2007.11.022Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). International Journal of Cardiology. 2009;131(2):293–5. DOI: 10.1016/j.ijcard.2007.11.022Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). International Journal of Cardiology. 2009;131(2):293–5. DOI: 10.1016/j.ijcard.2007.11.022Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). International Journal of Cardiology. 2009;131(2):293–5. DOI: 10.1016/j.ijcard.2007.11.022Gromova O.A., Torshin I.Yu., Kalacheva A.G., Grishina T.R., Egorova E.Yu. Regarding a Circadian Rhythm and Chronopharmacology of Magnesium Orotate. Effective pharmacotherapy. 2015;34:32–41. [Russian]Gromova O.A., Torshin I.Yu., Kalacheva A.G., Grishina T.R., Egorova E.Yu. Regarding a Circadian Rhythm and Chronopharmacology of Magnesium Orotate. Effective pharmacotherapy. 2015;34:32–41. [Russian]Gromova O.A., Torshin I.Yu., Kalacheva A.G., Grishina T.R., Egorova E.Yu. Regarding a Circadian Rhythm and Chronopharmacology of Magnesium Orotate. Effective pharmacotherapy. 2015;34:32–41. [Russian]Gromova O.A., Torshin I.Yu., Kalacheva A.G., Grishina T.R., Egorova E.Yu. Regarding a Circadian Rhythm and Chronopharmacology of Magnesium Orotate. Effective pharmacotherapy. 2015;34:32–41. [Russian]

The authors declare that there are no conflicts of interest present.